New Vaccine Development Establishing Priorities

VOLUME I

Diseases of Importance in the United States

Part One of a Two-Part Study by the Committee on Issues and Priorities for New Vaccine Development

Division of Health Promotion and Disease Prevention

INSTITUTE OF MEDICINE

NATIONAL ACADEMY PRESS

Washington, D.C.

1985

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page R1

Table of Contents

Front Matter R1-R14

1. Summary 1-16

2. Priority Setting for Health Related Investments: A Review of Methods 17-27

3. Overview of the Analytic Approach 28-38

4. Comparison of Disease Burdens and Costs 39-58

5. Predictions on Vaccine Development 59-66

6. Assessing the Likely Utilization of New Vaccines 67-91

7. Calculation and Comparison of the Health Benefits and Costs Associated with Candidate Vaccines 92-120

8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development 121-126

9. Findings, Conclusions, and Recommendations 127-148

Appendix A: Some Examples of the Application of Project Selection Method 149-152

Appendix B: Pathogenic Agents for Which Accelerated Vaccine Development Does Not Appear Appropriate 153-170

Appendix C: Prospects for Immunizing Against Bordetella pertussis 171-182

Appendix D: Prospects for Immunizing Against Coccidioidomycosis 183-197

Appendix E: Prospects for Immunizing Against Cytomegalovirus 198-234

Appendix F: Prospects for Immunizing Against Hemophilus influenzae type b 235-251

Appendix G: Prospects for Immunizing Against Hepatitis A Virus 252-260

Appendix H: Prospects for Immunizing Against Hepatitis B Virus 261-279

Appendix I: Prospects for Immunizing Against Herpes Simplex Viruses 1 and 2 280-312

Appendix J: Prospects for Immunizing Against Herpesvirus varicellae 313-341

Appendix K: Prospects for Immunizing Against Influenza Viruses A and B 342-364

Appendix L: Prospects for Immunizing Against Neisseria gonorrhoeae 365-384

Appendix M: Prospects for Immunizing Against Parainfluenza Viruses 385-396

Appendix N: Prospects for Immunizing Against Respiratory Syncytial Virus 397-409

Appendix O: Prospects for Immunizing Against Rotavirus 410-423

Appendix P: Prospects for Immunizing Against Streptococcus group B 424-439

Appendix Q: Questionnaire for Assessing Morbidity-Mortality Trade-Offs 440-443

Appendix R: Technical Notes 444-444

Appendix S: Biographical Notes on Committee Members 445-449

Appendix T: Additional Sources of Advice to the Committee 450-452

Index 453-458

New Vaccine Development Establishing Priorities